AMGEN INC 8-K

What Happened Amgen Inc. announced on April 22, 2026 that David M. Reese will retire from his role as Executive Vice President and Chief Technology Officer. To support integration of science, technology and data, Reese’s responsibilities will be redistributed effective June 1, 2026 to James E. Bradner (Executive VP, Research and Development, Artificial Intelligence and Data), Murdo Gordon (Executive VP, Amgen Global Markets and Policy), and Peter H. Griffith (Executive VP and Chief Financial Officer). Dr. Reese will remain employed as an Executive Vice President through his retirement date of June 30, 2026.

Key Details

• Announcement date: April 22, 2026; effective reassignment date: June 1, 2026; retirement date: June 30, 2026.
• Departing executive: David M. Reese, Executive VP & Chief Technology Officer.
• Responsibilities split among: James E. Bradner (R&D, AI & Data), Murdo Gordon (Global Markets & Policy), and Peter H. Griffith (CFO).
• Dr. Reese will be retirement-eligible under Amgen’s plans and will receive retirement benefits as described in company filings (including the 2026 Proxy Statement).

Why It Matters This is a management transition—not a sudden vacancy—designed to redistribute technology and data responsibilities across existing senior leaders. For investors, the filing signals continuity of leadership and a strategic move to align science, AI/data and commercial/policy functions under current executives. The 8-K does not report any immediate financial impacts, changes to executive compensation beyond standard retirement benefits, or changes to the CEO/CFO roles.